United States Generic Drugs Market By Segment (Generic, Branded), Therapeutic Application, Company Analysis & Forecast

March 2021 | 110 pages | ID: U48DBD910364EN
Renub Research

Abstracts

Generics are an off-patented drug that is pharmaceutical equivalents to branded medicines in term of administrative dosage, quality, effect, intended use and side effects. In the United States, generic drug production has increased because it is cheaper than any branded medicine. From the last 3 decades, U.S generic drug market has transformed from less than 20% of generic drug prescription to 80% of dispensing generic medicine prescriptions. As per the Renub Research report, United States Generic Drugs Market will be US$ 239.5 Billion by 2026.

Generic medicines help maintain the country's healthcare system, from curing patients to saving money. Currently, the price of off-label drugs is 70% to 80% lower than branded medicines. In the United States, the decline in medicine price works as the biggest catalyst for the generic drug market growth. These generic medicines prices sometimes declined to 85% less than patented drugs; this happens when various generic drug companies target a single patented drug. Our research findings suggest that the United States Off-Label Drugs Market will grow with a CAGR of 5.69% in future from 2020 to 2026.

The United States government awareness for the use of generic drugs reduces overall health expenditure in the country. The FDA's Office of Generic Drugs (OGD) within the Center for Drug Evaluation in Research ensures access to safe, high quality and affordable drugs to Americans. The U.S government made a law regarding the generic drug, allowing a new player to enter the market. Besides factors like the rising number of patients for diabetes, Alzheimer, cardiac diseases, an increasing number of drug patent expirations and government initiatives expected to drive the generic drugs industry. As per this research study, the United States Off-patent Drugs Market was US$ 171.8 Billion in the year 2020.

Generic Drug Companies Deals

On July 6, 2020, Endo announced that it had received FDA approval of Qwo® (collagenase clostridium histolyticum-aaes). Another company, named Lupin Limited manufactures generic drug Abacavir& Lamivudine, whose combination is being used together with other medications to treat human immunodeficiency virus (HIV) infection. We have covered companies’ initiatives that sell various generic drugs in the United States. Companies covered in the report are Teva Pharmaceutical Industries Ltd, Mylan N.V, Sandoz Inc, Endo Pharmaceuticals, Lupin Limited, Dr Reddy's and Sun pharma.

Renub Research report title “United States Generic Drugs Market’’ By Segment (Generic, Branded), Therapeutic Application (CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective, Oncology and Others), Pharmaceutical (Branded Pharmaceutical, Generics Pharmaceutical), Company (Teva Pharmaceutical Industries Ltd, Mylan N.V, Sandoz Inc, Endo Pharmaceuticals, Lupin Limited, Dr Reddy's and Sun pharma)” provides an all-encompassing analysis on the US Generic Drug Industry.

Segment: Market breakup from 2 viewpoints

• Generic
• Branded

Therapeutic Application: Market breakup from 8 viewpoints

1. CNS
2. Cardiovascular
3. Dermatology
4. Genitourinary/Hormonal
5. Respiratory
6. Anti-infective
7. Oncology
8. Others

Pharmaceutical: Market breakup from 2 viewpoints

• Branded Pharmaceutical
• Generics Pharmaceutical

All the Company Analysis have covered 3 Viewpoints

• Overview
• Recent Developments
• Revenue Analysis

Company Analysis

1. Teva Pharmaceutical Industries Ltd
2. Mylan N.V
3. Sandoz Inc.
4. Endo Pharmaceuticals
5. Lupin Limited
6. Dr Reddy's
7. Sun pharma

Contents

1. INTRODUCTION

2. EXECUTIVE SUMMARY

3. MARKET DYNAMICS

3.1 Growth Driver
3.2 Challenges

4. UNITED STATES DRUGS MARKET

4.1 Branded Drugs Market
4.2 Generics Drugs Market

5. UNITED STATES GENERIC DRUGS SAVING

6. MARKET SHARE – UNITED STATES DRUGS ANALYSIS

6.1 Branded vs. Generics Drugs
6.2 Branded Generic vs. Unbranded Generic Drug
6.3 Volume Penetration – Generic vs. Branded Drugs
6.4 Therapeutic Application

7. UNITED STATES GENERIC DRUGS MARKET

7.1 Branded Generic Drugs Market
7.2 Unbranded Generic Drugs Market

8. THERAPEUTIC APPLICATION – UNITED STATES GENERIC DRUGS MARKET

8.1 Central Nervous System (CNS)
8.2 Cardiovascular
8.3 Dermatology
8.4 Genitourinary / Hormonal Drugs
8.5 Respiratory
8.6 Anti-infective
8.7 Oncology
8.8 Others

9. COMPANY ANALYSIS

9.1 Teva Pharmaceutical Industries Ltd
  9.1.1 Overview
  9.1.2 Product Launch
  9.1.3 Financial Insight
9.2 Mylan N.V.
  9.2.1 Overview
  9.2.2 Product Launch
  9.2.3 Financial Insight
9.3 Sandoz Inc.
  9.3.1 Overview
  9.3.2 Product Launch
  9.3.3 Financial Insight
9.4 Endo Pharmaceuticals
  9.4.1 Overview
  9.4.2 Product Launch
  9.4.3 Financial Insight
9.5 Lupin Limited
  9.5.1 Overview
  9.5.2 Product Launch
  9.5.3 Financial Insight
9.6 Dr Reddy's
  9.6.1 Overview
  9.6.2 Product Launch
  9.6.3 Financial Insight
9.7 Sun Pharmaceutical Industries Ltd.
  9.7.1 Overview
  9.7.2 Product Launch
  9.7.3 Financial Insight

List Of Figures

LIST OF FIGURES:

Figure 3-1: United States – Rising Geriatric Population (Million), 2000, 2016 & 2060
Figure 4-1: US – Pharma Market (Billion US$), 2015 – 2020
Figure 4-2: US – Forecast for Pharma Market (Billion US$), 2021 – 2026
Figure 4-3: US– Branded Pharma Market (Billion US$), 2015 – 2020
Figure 4-4: US – Forecast for Branded Pharma Market (Billion US$), 2021 – 2026
Figure 4-5: US– Generics Pharma Market (Billion US$), 2015 – 2020
Figure 4-6: US – Forecast for Generics Pharma Market (Billion US$), 2021 – 2026
Figure 5-1: Top 10 Generic Drugs Ranked by Savings in US – 2016
Figure 5-2: Ten Major US State Generic Saving in – 2016
Figure 5-3: Savings from Generics in (Billions US$), – 2016
Figure 5-4: US – Generic Drugs Saving (Billion US$), 2015 – 2020
Figure 5-5: US – Forecast for GenericDrugs Saving (Billion US$), 2021 – 2026
Figure 6-1: Branded VS Generic Drug Market Share (%), 2015 – 2020
Figure 6-2: Forecast for – Branded VS Generic Drug Market Share (%), 2021 – 2026
Figure 6-3: Branded Generic vs. Unbranded Market Share (%), 2015 – 2020
Figure 6-4: Forecast for – Branded Generic vs. Unbranded Market Share (%), 2021 – 2026
Figure 6-5: Generic V.S. Branded Drug Volume Penetration (%), 2015 – 2020
Figure 6-6: Forecast for – Generic V.S. Branded Drug Volume Penetration (%), 2021 – 2026
Figure 7-1: Branded – Generic Drug Market (Billion US$), 2015 – 2020
Figure 7-2: Branded – Forecast for Generic Drug Market (Billion US$), 2021 – 2026
Figure 7-3: Unbranded – Generic Drug Market (Billion US$), 2015 – 2020
Figure 7-4: Unbranded – Forecast for Generic Drug Market (Billion US$), 2021 – 2026
Figure 8-1: Central Nervous System Market (Billion US$), 2015 – 2020
Figure 8-2: Forecast for – Central Nervous System Market (Billion US$), 2021 – 2026
Figure 8-3: U.S Incidence of cardiovascular disease by age and sex – 2013
Figure 8-4: Cardiovascular Market (Billion US$), 2015 – 2020
Figure 8-5: Forecast for Cardiovascular Market (Billion US$), 2021 – 2026
Figure 8-6: Skin Diseases Prevalence in US – 2013
Figure 8-7: Dermatology Market (Million US$), 2015 – 2020
Figure 8-8: Forecast for – Dermatology Market (Million US$), 2021 – 2026
Figure 8-9: Genitourinary/Hormonal Drugs Market (Billion US$), 2015 – 2020
Figure 8-10: Forecast for – Genitourinary/Hormonal Drugs Market (Billion US$), 2021 – 2026
Figure 8-11: Respiratory Market (Billion US$), 2015 – 2020
Figure 8-12: Forecast for – Respiratory Market (Billion US$), 2021 – 2026
Figure 8-13: Anti – infective Market (Billion US$), 2015 – 2020
Figure 8-14: Forecast for Anti – infective Market (Billion US$), 2021 – 2026
Figure 8-15: Oncology Market (Billion US$), 2015 – 2020
Figure 8-16: Forecast for – Oncology Market (Billion US$), 2021 – 2026
Figure 8-17: Others Market (Billion US$), 2015 – 2020
Figure 8-18: Forecast for – Others Market (Billion US$), 2021 – 2026
Figure 9-1: Teva – US Generic Drugs Market (Million US$), 2015 – 2020
Figure 9-2: Teva – Forecast for US Generic Drugs Market (Million US$), 2020 – 2026
Figure 10-1: Mylan NV – US Generic Drugs Market (Million US$), 2015 – 2020
Figure 10-2: Mylan NV – Forecast for Mylan NV US Generic Drugs Market (Million US$), 2021 – 2026
Figure 11-1: Sandoz – US Generic Drugs Market (Million US$), 2015 – 2020
Figure 11-2: Sandoz – Forecast for Sandoz US Generic Drugs Market (Million US$), 2021 – 2026
Figure 12-1: Endo Pharmaceuticals – US Generic Drugs Market (Million US$), 2015 – 2020
Figure 12-2: Endo Pharmaceuticals – Forecast for US Generic Drugs Market (Million US$), 2021 – 2026
Figure 13-1: Lupin Limited – US Generic Drugs Market (Million US$), 2015 – 2020
Figure 13-2: Lupin Limited – Forecast for US Generic Drugs Market (Million US$), 2021 – 2026
Figure 14-1: Dr Reddy’s – North America (US & Canada) Generic Drugs Market (Million US$), 2015 – 2020
Figure 14-2: Dr Reddy’s – Forecast for North America (US & Canada) Generic Drugs Market (Million US$), 2021 – 2026
Figure 15-1: Sun Pharma – US Generic Drugs Market (Million US$), 2015 – 2020
Figure 15-2: Sun Pharma – Forecast for US Generic Drugs Market (Million US$), 2021 – 2026
Figure 16-1: Others – US Generic Drugs Market (Million US$), 2015 – 2020
Figure 16-2: Others – Forecast for US Generic Drugs Market (Million US$), 2021 – 2026

List Of Tables

LIST OF TABLES:

Table 6-1: US Generic Drugs – Therapeutic Application Market Share (%), 2015 – 2020
Table 6-2: US Generic Drugs – Forecast for Therapeutic Application Market Share (%), 2021 – 2026
Table 8-1: The Full Burden of 24 Skin Disease categories